Header Logo

FREDRICK B HAGEMEISTER

TitleProfessor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase?1/2?trial. EClinicalMedicine. 2024 Aug; 74:102747. PMID: 39161543; PMCID: PMC11332795.
      Citations:    
    2. Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, M?ller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res. 2023 12 01; 29(23):4808-4821. PMID: 37728879; PMCID: PMC10842978.
      Citations: 2     Fields:    Translation:HumansCells
    3. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885. PMID: 37985359; PMCID: PMC10922670.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, M?ller MB, Piris MA, Wang Y, Zhang M, Young KH. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 04 11; 7(7):1308-1311. PMID: 36399513; PMCID: PMC10119604.
      Citations: 1     Fields:    Translation:Cells
    5. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145. PMID: 36375046; PMCID: PMC10111343.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol. 2023 Mar 20; 12(1):32. PMID: 36941707; PMCID: PMC10026479.
      Citations:    
    7. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022 09 06; 3(5):428-443. PMID: 35687817; PMCID: PMC9894575.
      Citations:    Fields:    
    8. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44. PMID: 36068929; PMCID: PMC9771924.
      Citations:    
    9. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755. PMID: 35952327; PMCID: PMC10489211.
      Citations:    
    10. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515. PMID: 35512184; PMCID: PMC9353148.
      Citations:    Fields:    
    11. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPa+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv. 2022 06 14; 6(11):3286-3293. PMID: 35359004; PMCID: PMC9198921.
      Citations:    Fields:    Translation:HumansCells
    12. Khan M, Hagemeister F, Wang M, Ahmed S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Rev. 2022 09; 55:100949. PMID: 35396126.
      Citations:    Fields:    
    13. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH, Nagy M, Ferreri AJM, M?ller MB, Piris MA. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983. PMID: 34980601; PMCID: PMC9137388.
      Citations: 1     Fields:    Translation:Humans
    14. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Li Y, Xu B, Young KH, Ferreri AJM, M?ller MB, Piris MA. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25. PMID: 35105854; PMCID: PMC8807629.
      Citations: 1     Fields:    Translation:HumansCells
    15. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415. PMID: 35074072.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    16. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212. PMID: 34797699; PMCID: PMC8718245.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    17. Khan M, Samaniego F, Hagemeister FB, Iyer SP. Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers (Basel). 2021 Nov 10; 13(22). PMID: 34830782; PMCID: PMC8616039.
      Citations:    
    18. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672. PMID: 32732355; PMCID: PMC8485681.
      Citations: 19     Fields:    Translation:Humans
    19. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 01; 63(1):74-83. PMID: 34435552; PMCID: PMC9284943.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/d in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021 12; 62(14):3452-3462. PMID: 34365878.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    21. You H, Xu-Monette ZY, Wei L, Nunns H, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Parsons BM, Van Krieken JH, Piris MA, Li Y, Au Q, Xu B, Albitar M, Young KH, Nagy ML, Ferreri AJM, M?ller MB, Winter JN. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology. 2021; 10(1):1928365. PMID: 34350060; PMCID: PMC8293967.
      Citations: 3     Fields:    Translation:Humans
    22. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374. PMID: 33735664; PMCID: PMC7985670.
      Citations: 2     Fields:    Translation:Humans
    23. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood. 2021 02 25; 137(8):1124-1129. PMID: 32932518; PMCID: PMC7907727.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    24. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Parsons BM, Hagemeister F, van Krieken JH, Winter JN, Li Y, Xu B, Liu P, Young KH, Ferreri AJM, M?ller MB, Piris MA. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260. PMID: 33154093; PMCID: PMC8092941.
      Citations: 5     Fields:    Translation:HumansCells
    25. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH, Ferreri AJM, M?ller MB, Piris MA. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148. PMID: 33148342; PMCID: PMC7641823.
      Citations: 10     Fields:    Translation:HumansCells
    26. Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol. 2020 12; 191(5):806-815. PMID: 33065767.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    27. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587. PMID: 33055173.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    28. Yu L, Shi M, Cai Q, Strati P, Hagemeister F, Zhai Q, Li L, Fang X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, Sato Y, Zhang L, Li J, Xu-Monette ZY, Young KH, Oksenhendler E. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. Oncologist. 2020 11; 25(11):963-973. PMID: 32852137; PMCID: PMC7648372.
      Citations: 2     Fields:    Translation:HumansCells
    29. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67. PMID: 32924687.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    30. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951. PMID: 32822484; PMCID: PMC7448589.
      Citations: 18     Fields:    Translation:Humans
    31. Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH, Ferreri AJM, M?ller MB, Piris MA. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 07 28; 4(14):3391-3404. PMID: 32722783; PMCID: PMC7391158.
      Citations: 6     Fields:    Translation:HumansCells
    32. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation? Bone Marrow Transplant. 2021 01; 56(1):278-281. PMID: 32636464.
      Citations: 2     Fields:    Translation:Humans
    33. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Piris MA, Young KH, Montes-Moreno S. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49. PMID: 32366834; PMCID: PMC7198569.
      Citations: 10     Fields:    Translation:HumansCells
    34. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 06; 61(6):1380-1387. PMID: 31971032.
      Citations: 1     Fields:    Translation:Humans
    35. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020 07; 105(7):1907-1913. PMID: 31601688; PMCID: PMC7327641.
      Citations: 7     Fields:    Translation:Humans
    36. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336. PMID: 31533521.
      Citations: 1     Fields:    Translation:Humans
    37. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):709-714. PMID: 31446000.
      Citations: 1     Fields:    Translation:Humans
    38. Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-associated Serositis in Mantle Cell Lymphoma. Am J Respir Crit Care Med. 2019 06 15; 199(12):e43-e44. PMID: 30802411; PMCID: PMC6580678.
      Citations: 1     Fields:    Translation:Humans
    39. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28. PMID: 31073068; PMCID: PMC6939506.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    40. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. 2019 May/Jun; 35(3):243-246. PMID: 30124609.
      Citations: 2     Fields:    Translation:Humans
    41. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882. PMID: 30919940; PMCID: PMC6619290.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    42. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol. 2019 06; 94(6):E150-E153. PMID: 30785215.
      Citations: 1     Fields:    Translation:HumansCells
    43. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019 05; 185(4):670-678. PMID: 30820940.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    44. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346. PMID: 30763728; PMCID: PMC8265611.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    45. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365; PMCID: PMC6200878.
      Citations: 3     
    46. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461. PMID: 29538376; PMCID: PMC5851529.
      Citations: 10     Fields:    Translation:Humans
    47. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018 02; 180(4):545-549. PMID: 29271057.
      Citations: 12     Fields:    Translation:HumansCells
    48. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108. PMID: 29196178.
      Citations: 1     Fields:    Translation:Humans
    49. Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B, Thuro BA. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct; 33(5):355-360. PMID: 27636243.
      Citations: 3     Fields:    Translation:Humans
    50. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    51. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477. PMID: 28522441; PMCID: PMC5578726.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    52. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844. PMID: 28482717; PMCID: PMC6042648.
      Citations: 5     Fields:    Translation:Humans
    53. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553. PMID: 28408615; PMCID: PMC5423503.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    54. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270. PMID: 28340281; PMCID: PMC5901692.
      Citations: 5     Fields:    Translation:Humans
    55. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760; PMCID: PMC5836501.
      Citations: 27     Fields:    Translation:Humans
    56. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854. PMID: 27502933; PMCID: PMC6063086.
      Citations: 6     Fields:    Translation:Humans
    57. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299. PMID: 27448187.
      Citations: 12     Fields:    Translation:HumansCells
    58. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506. PMID: 27378601; PMCID: PMC5920532.
      Citations: 3     Fields:    Translation:Humans
    59. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151. PMID: 27351173.
      Citations: 25     Fields:    Translation:Humans
    60. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 07; 27(7):1317-23. PMID: 27091808; PMCID: PMC6357675.
      Citations: 10     Fields:    Translation:Humans
    61. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016 05; 27(5):895-901. PMID: 26802151.
      Citations: 7     Fields:    Translation:Humans
    62. Sathyanarayanan V, Hagemeister F. Targeted therapies for Hodgkin lymphoma: results of recent trials. Rinsho Ketsueki. 2016; 57(10):2049-2053. PMID: 27795513.
      Citations:    Fields:    Translation:HumansCells
    63. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083; PMCID: PMC9754636.
      Citations: 5     Fields:    Translation:Humans
    64. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan; 172(1):80-8. PMID: 26648336; PMCID: PMC5471614.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    65. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140; PMCID: PMC4715651.
      Citations: 28     Fields:    Translation:HumansCells
    66. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16. PMID: 26260306.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    67. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759; PMCID: PMC4418191.
      Citations: 13     Fields:    Translation:Humans
    68. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764; PMCID: PMC4418193.
      Citations: 43     Fields:    Translation:Humans
    69. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23. PMID: 25828695; PMCID: PMC5278955.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    70. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4. PMID: 25820332; PMCID: PMC4486240.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    71. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179. PMID: 25712454.
      Citations: 39     Fields:    Translation:Humans
    72. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689; PMCID: PMC4370362.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    73. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    74. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868; PMCID: PMC5279071.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    75. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 105     Fields:    Translation:Humans
    76. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91. PMID: 24721592.
      Citations: 3     Fields:    Translation:Humans
    77. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol. 2014 Apr; 25(4):913-914. PMID: 24667725.
      Citations: 1     Fields:    Translation:Humans
    78. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6. PMID: 24386943; PMCID: PMC5308126.
      Citations: 15     Fields:    Translation:Humans
    79. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77. PMID: 24332512; PMCID: PMC3922714.
      Citations: 225     Fields:    Translation:HumansCTClinical Trials
    80. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care? J Comp Eff Res. 2013 Nov; 2(6):537-40. PMID: 24236792.
      Citations: 1     Fields:    Translation:Humans
    81. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90. PMID: 24097867; PMCID: PMC4409814.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    82. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234; PMCID: PMC5278952.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    83. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(?) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8. PMID: 23802738.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    84. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8. PMID: 23488661; PMCID: PMC3827734.
      Citations: 9     Fields:    Translation:Humans
    85. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013 Jul; 162(1):138-41. PMID: 23590726.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    86. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    87. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9. PMID: 23310949; PMCID: PMC4332882.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    88. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105. PMID: 23276888; PMCID: PMC3881262.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    89. Hagemeister FB. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy? BioDrugs. 2012 Dec 01; 26(6):363-76. PMID: 23057946.
      Citations: 1     Fields:    Translation:Humans
    90. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):15-8. PMID: 23137719; PMCID: PMC4623568.
      Citations: 10     Fields:    Translation:HumansCells
    91. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012 Nov 20; 30(33):4161-7. PMID: 22965964; PMCID: PMC5950499.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    92. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012 Aug 01; 30(22):2776-82. PMID: 22753910; PMCID: PMC5950497.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    93. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    94. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012 Mar 01; 119(9):2171-2. PMID: 22383790.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    95. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    96. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma. 2012 May; 53(5):801-6. PMID: 22023528.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    97. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan; 53(1):50-6. PMID: 21895545; PMCID: PMC4104165.
      Citations: 11     Fields:    Translation:Humans
    98. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451; PMCID: PMC4110463.
      Citations: 21     Fields:    Translation:Humans
    99. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66. PMID: 21191675; PMCID: PMC4394740.
      Citations: 10     Fields:    Translation:Humans
    100. Hagemeister FB. Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. Curr Oncol Rep. 2010 Nov; 12(6):395-401. PMID: 20820960.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    101. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10):935-41. PMID: 20920696.
      Citations: 14     Fields:    Translation:Humans
    102. Morris GJ, Dotan E, Smith MR, Hagemeister FB, Brereton HD. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol. 2010 Jun; 37(3):183-7. PMID: 20709202.
      Citations:    Fields:    Translation:HumansCells
    103. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8. PMID: 20528872.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    104. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2010 Feb 12; 70(3):261-72. PMID: 20166765.
      Citations: 21     Fields:    Translation:Humans
    105. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009 Nov; 9(11):1445-51. PMID: 19817678.
      Citations: 29     Fields:    Translation:Humans
    106. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8. PMID: 19770379.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    107. Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin's lymphomas. Onco Targets Ther. 2009 Feb 18; 2:269-79. PMID: 20616914; PMCID: PMC2886317.
      Citations: 2     
    108. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52. PMID: 19168784; PMCID: PMC4624445.
      Citations: 49     Fields:    Translation:Humans
    109. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009 Apr; 20(4):709-14. PMID: 19150940.
      Citations: 17     Fields:    Translation:Humans
    110. Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A, Morschhauser F. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist. 2009; 14 Suppl 2:17-29. PMID: 19819921.
      Citations: 14     Fields:    Translation:Humans
    111. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41. PMID: 18973182.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    112. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008 Nov; 143(3):355-60. PMID: 18764869.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    113. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6. PMID: 18411419; PMCID: PMC4624452.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    114. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15; 112(4):831-6. PMID: 18085611.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    115. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64. PMID: 18223284; PMCID: PMC4238917.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    116. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008 Mar; 19(3):553-9. PMID: 18083690.
      Citations: 6     Fields:    Translation:Humans
    117. Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol. 2007 Aug; 5(8 Suppl 12):4-20; quiz 1 p following 20. PMID: 18154235.
      Citations:    Fields:    Translation:Humans
    118. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007 Aug; 82(8):725-8. PMID: 17373675.
      Citations: 40     Fields:    Translation:HumansCells
    119. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5. PMID: 17608763.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    120. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007 Jun 15; 109(12):2481-9. PMID: 17497648.
      Citations: 45     Fields:    Translation:Humans
    121. Hagemeister FB. Hodgkin's lymphoma in younger patients: lessons learned on the road to success. Oncology (Williston Park). 2007 Apr; 21(4):434-40; discussion 441-2, 445-6. PMID: 17474345.
      Citations:    Fields:    Translation:Humans
    122. Fayad L, Hagemeister F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. Leuk Lymphoma. 2007 Apr; 48(4):657-8. PMID: 17454622.
      Citations:    Fields:    Translation:Humans
    123. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47. PMID: 17233846.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    124. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7. PMID: 17054068.
      Citations: 13     Fields:    Translation:HumansCells
    125. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302. PMID: 16902984.
      Citations: 28     Fields:    Translation:Humans
    126. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1818-21. PMID: 17064994.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    127. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80. PMID: 16502413.
      Citations: 156     Fields:    Translation:HumansCTClinical Trials
    128. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 01; 24(10):1582-9. PMID: 16575009.
      Citations: 43     Fields:    Translation:Humans
    129. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Mar; 47(3):481-5. PMID: 16396772.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    130. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23. PMID: 16145068.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    131. Poonawalla T, Jones D, Hagemeister F, Duvic M. Acral necrotizing mycosis fungoides. Clin Lymphoma Myeloma. 2005 Sep; 6(2):146-8. PMID: 16231855.
      Citations: 2     Fields:    Translation:Humans
    132. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15; 104(4):781-7. PMID: 15973667.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    133. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005 Jul 15; 104(2):345-53. PMID: 15948158.
      Citations: 4     Fields:    Translation:Humans
    134. Hagemeister FB. Stem-cell transplant for Hodgkin's lymphoma: does choice of therapy prior to high-dose treatment matter? Nat Clin Pract Oncol. 2005 Jul; 2(7):344-5. PMID: 16075792.
      Citations:    Fields:    
    135. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005 Jun 15; 105(12):4573-5. PMID: 15741224; PMCID: PMC1895007.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    136. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist. 2005 Feb; 10(2):150-9. PMID: 15709217.
      Citations: 6     Fields:    Translation:Humans
    137. Romaguera J, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol. 2005 Jan; 21(1):80-4. PMID: 15687889.
      Citations: 18     Fields:    Translation:Humans
    138. Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer J. 2005 Jan-Feb; 11 Suppl 1:S1-10. PMID: 15835720.
      Citations:    Fields:    Translation:Humans
    139. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75. PMID: 15613697.
      Citations: 122     Fields:    Translation:HumansCTClinical Trials
    140. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102. PMID: 15353540.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    141. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8. PMID: 15328181.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    142. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      Citations: 13     Fields:    Translation:Humans
    143. Khoury JD, Jones D, Yared MA, Manning JT, Abruzzo LV, Hagemeister FB, Medeiros LJ. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004 Apr; 28(4):489-95. PMID: 15087668.
      Citations: 7     Fields:    Translation:HumansCells
    144. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer. 2004 Mar 15; 100(6):1186-9. PMID: 15022285.
      Citations: 7     Fields:    Translation:Humans
    145. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol. 2004 Feb; 27(1):73-80. PMID: 14758137.
      Citations: 6     Fields:    Translation:Humans
    146. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8. PMID: 12883733.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    147. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15; 98(2):310-4. PMID: 12872350.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    148. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003 Jun 01; 21(11):2115-22. PMID: 12775737.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    149. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 01; 97(3):586-91. PMID: 12548600.
      Citations: 67     Fields:    Translation:Humans
    150. Hagemeister FB. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy. Clin Adv Hematol Oncol. 2003 Feb; 1(2):120-5. PMID: 16224391.
      Citations:    Fields:    Translation:Humans
    151. Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Cancer Res. 2003 Jan 01; 63(1):44-51. PMID: 12517776.
      Citations: 20     Fields:    Translation:HumansCells
    152. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jan 01; 55(1):36-43. PMID: 12504034.
      Citations: 2     Fields:    Translation:Humans
    153. Hagemeister FB. Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy. Leuk Lymphoma. 2003; 44 Suppl 3:S69-75. PMID: 15202528.
      Citations:    Fields:    Translation:Humans
    154. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002 Dec 15; 95(12):2534-8. PMID: 12467067.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    155. Gibson AD, D'Orazio A. VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland. Clin Lymphoma. 2002 Sep; 3(2):75-81. PMID: 12435279.
      Citations:    Fields:    Translation:Humans
    156. Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002 Sep-Oct; 8(5):377-83. PMID: 12416895.
      Citations: 12     Fields:    Translation:Humans
    157. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002 Dec 15; 100(13):4351-7. PMID: 12393618.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    158. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31. PMID: 12199630.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    159. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002 May; 49 Suppl 1:S13-20. PMID: 12042984.
      Citations: 14     Fields:    Translation:Humans
    160. Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002 Mar 15; 94(6):1731-8. PMID: 11920535.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    161. Barista I, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros LJ, Hagemeister FB. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol. 2002 Feb; 13(2):318-22. PMID: 11886011.
      Citations: 7     Fields:    Translation:Humans
    162. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9. PMID: 11739162.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    163. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001 Sep 01; 19(17):3766-70. PMID: 11533100.
      Citations: 25     Fields:    Translation:Humans
    164. Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys. 2001 Jul 15; 50(4):971-7. PMID: 11429225.
      Citations: 3     Fields:    Translation:Humans
    165. Hagemeister FB, Diehl V. The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas. Eur J Haematol Suppl. 2001 Jul; 64:1-2. PMID: 11486394.
      Citations:    Fields:    Translation:Humans
    166. Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. Eur J Haematol Suppl. 2001 Jul; 64:8-13. PMID: 11486405.
      Citations:    Fields:    Translation:Humans
    167. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001 Jul; 12(7):923-7. PMID: 11521796.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    168. Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park). 2001 Jul; 15(7 Suppl 8):53-6. PMID: 11497233.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    169. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001 Jun; 2(1):40-6. PMID: 11707869.
      Citations: 11     Fields:    Translation:Humans
    170. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44. PMID: 11378571.
      Citations: 1     Fields:    Translation:Humans
    171. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405. PMID: 11208831.
      Citations: 2     Fields:    Translation:Humans
    172. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6. PMID: 11205462.
      Citations: 4     Fields:    Translation:Humans
    173. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000 Dec; 27(6 Suppl 12):37-41. PMID: 11225999.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    174. Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec; 40(1-2):79-85. PMID: 11426631.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    175. Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma. 2000 Oct; 39(3-4):291-9. PMID: 11342309.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    176. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85. PMID: 10975386.
      Citations: 9     Fields:    Translation:Humans
    177. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Manning J, Romaguera J, Sarris A, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE, K?rbling MJ. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20. PMID: 11041566.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    178. Dubey P, Wilson G, Mathur KK, Hagemeister FB, Fuller LM, Ha CS, Cox JD, Meistrich ML. Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Int J Radiat Oncol Biol Phys. 2000 Feb 01; 46(3):609-17. PMID: 10701740.
      Citations: 6     Fields:    Translation:Humans
    179. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72. PMID: 10690390.
      Citations: 31     Fields:    Translation:HumansAnimalsCTClinical Trials
    180. Moore IK, Martin MP, Dorsey MJ, Paquin CE. Formation of circular amplifications in Saccharomyces cerevisiae by a breakage-fusion-bridge mechanism. Environ Mol Mutagen. 2000; 36(2):113-20. PMID: 11013409.
      Citations: 7     Fields:    Translation:AnimalsCells
    181. Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS, L?pez-Guillermo A, Rodr?guez MA. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000; 11 Suppl 1:137-40. PMID: 10707796.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    182. Zheng N, Monckton DG, Wilson G, Hagemeister F, Chakraborty R, Connor TH, Siciliano MJ, Meistrich ML. Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy. Environ Mol Mutagen. 2000; 36(2):134-45. PMID: 11013412.
      Citations: 10     Fields:    Translation:HumansCells
    183. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    184. McLaughlin P, Hagemeister FB, Grillo-L?pez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999 Oct; 26(5 Suppl 14):79-87. PMID: 10561022.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    185. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma. 1999 Aug; 34(5-6):433-41. PMID: 10492066.
      Citations: 1     Fields:    Translation:Humans
    186. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug; 17(8):2461-70. PMID: 10561310.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    187. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95. PMID: 10419446.
      Citations: 52     Fields:    Translation:HumansCells
    188. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 01; 93(11):3632-6. PMID: 10339468.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    189. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R, K?rbling M. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      Citations: 15     Fields:    Translation:Humans
    190. Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS, L?pez-Guillermo A, Rodr?guez MA. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999 May 01; 93(9):3081-7. PMID: 10216105.
      Citations: 12     Fields:    Translation:HumansCells
    191. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40. PMID: 10370786.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    192. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999 Apr 01; 93(7):2202-7. PMID: 10090928.
      Citations: 8     Fields:    Translation:Humans
    193. Ha CS, Kavadi V, Dimopoulos MA, Hagemeister FB, Osborne BM, Fuller LM, Smith TL, Hess MA, McLaughlin PW, Cabanillas FF, Cox JD. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):329-34. PMID: 10030257.
      Citations:    Fields:    Translation:HumansCells
    194. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs. 1999; 17(2):187-92. PMID: 10638491.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    195. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9. PMID: 9850025.
      Citations: 61     Fields:    Translation:Humans
    196. Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol. 1998 Dec; 103(3):678-83. PMID: 9858216.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    197. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106. PMID: 10037005.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    198. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Hess MA, Tucker SL, Cabanillas F, Cox JD. Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology. 1998 Sep; 208(3):739-47. PMID: 9722855.
      Citations:    Fields:    Translation:HumansPHPublic Health
    199. Liao Z, Ha CS, Fuller LM, Hagemeister FB, Cabanillas F, Tucker SL, Hess MA, Cox JD. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1047-56. PMID: 9719114.
      Citations: 3     Fields:    Translation:Humans
    200. Cabanillas F, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera JE, Dong K, Moon T, Rodriguez-Diaz Pav?n J. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol. 1998 May; 9(5):511-8. PMID: 9653492.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    201. Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS, L?pez-Guillermo A, Rodr?guez MA. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998 Apr 15; 91(8):2955-60. PMID: 9531606.
      Citations: 10     Fields:    Translation:Humans
    202. Bouvet M, Staerkel GA, Spitz FR, Curley SA, Charnsangavej C, Hagemeister FB, Janjan NA, Pisters PW, Evans DB. Primary pancreatic lymphoma. Surgery. 1998 Apr; 123(4):382-90. PMID: 9551063.
      Citations: 13     Fields:    Translation:Humans
    203. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84. PMID: 9454747.
      Citations: 62     Fields:    Translation:Humans
    204. Cather JC, Jackow C, Yegge J, Hagemeister F, Duvic M. Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome. J Am Acad Dermatol. 1998 Feb; 38(2 Pt 2):301-5. PMID: 9486702.
      Citations: 2     Fields:    Translation:Humans
    205. Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG. Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):377-86. PMID: 9457824.
      Citations:    Fields:    Translation:Humans
    206. Romaguera JE, Hagemeister FB, McLaughlin P, Sarris AH, Younes A, Preti A, Bachier C, Llerena E, Cabanillas F, Rodr?guez D?az-Pavon J, Car?as L, Rodr?guez MA. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma. 1998 Jan; 28(3-4):295-306. PMID: 9517501.
      Citations: 2     Fields:    Translation:Humans
    207. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol. 1997 Dec; 15(12):3488-95. PMID: 9396402.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    208. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):609-16. PMID: 9336140.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    209. Vlachaki MT, Hagemeister FB, Fuller LM, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. Int J Radiat Oncol Biol Phys. 1997 Jun 01; 38(3):593-9. PMID: 9231684.
      Citations: 2     Fields:    Translation:Humans
    210. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jun; 26(1-2):77-82. PMID: 9250790.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    211. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet. 1997 May; 16(1):74-8. PMID: 9140398.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    212. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997 Feb; 96(2):328-32. PMID: 9029021.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    213. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol. 1997; 8 Suppl 1:129-31. PMID: 9187446.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    214. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med. 1997 Jan; 102(1):21-8. PMID: 9209197.
      Citations: 18     Fields:    Translation:Humans
    215. Younes A, Cabanillas F, McLaughlin PW, Hagemeister FB, Farber C, Sarris A, Pate O, Myers J, Portlock C. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol. 1996 Dec; 7(10):1083-5. PMID: 9037370.
      Citations:    Fields:    Translation:Humans
    216. Fayad L, Robertson LE, O'Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk Lymphoma. 1996 Oct; 23(3-4):333-7. PMID: 9031114.
      Citations: 10     Fields:    Translation:Humans
    217. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996 Apr; 14(4):1262-8. PMID: 8648382.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    218. Hagemeister FB. Hodgkin's disease: the next decade. Leuk Lymphoma. 1996 Mar; 21(1-2):53-61. PMID: 8907270.
      Citations:    Fields:    Translation:Humans
    219. Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol. 1996 Feb; 14(2):543-8. PMID: 8636769.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    220. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol. 1996 Feb; 7(2):157-63. PMID: 8777172.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    221. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1996 Jan; 14(1):233-9. PMID: 8558203.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    222. Hagemeister FB. Treatment of small non-cleaved cell lymphoma in the adult. Biomed Pharmacother. 1996; 50(9):433-41. PMID: 8991114.
      Citations:    Fields:    Translation:Humans
    223. Hagemeister FB. Low-grade lymphomas: new entities and treatment concepts. Med Oncol. 1995 Sep; 12(3):131-42. PMID: 8852395.
      Citations:    Fields:    Translation:Humans
    224. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul; 13(7):1734-41. PMID: 7602363.
      Citations: 11     Fields:    Translation:Humans
    225. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul; 6(6):609-11. PMID: 8573542.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    226. Suki S, Swan F, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma. 1995 Jun; 18(1-2):87-92. PMID: 8580834.
      Citations: 3     Fields:    Translation:Humans
    227. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995 May; 17(5-6):427-33. PMID: 7549833.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    228. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995 Mar; 13(3):583-7. PMID: 7884419.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    229. Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol). 1995; 7(5):300-3. PMID: 8580055.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    230. Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol. 1995 Jan-Feb; 13(1):19-27. PMID: 7750925.
      Citations: 4     Fields:    Translation:Humans
    231. Fuller LM, Krasin MJ, Velasquez WS, Allen PK, McLaughlin P, Rodriguez MA, Hagemeister FB, Swan F, Cabanillas F, Palmer JL, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):3-11. PMID: 7527799.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    232. Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994 Nov; 5(9):847-9. PMID: 7848887.
      Citations: 5     Fields:    Translation:Humans
    233. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med. 1994 Nov 01; 121(9):633-40. PMID: 7944070.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    234. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun; 12(6):1169-76. PMID: 8201379.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    235. Velasquez WS, McLaughlin P, Fuller LM, Allen PK, Tucker SL, Swan F, Rodriguez MA, Hagemeister FB, Cabanillas FF. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer. 1994 May 01; 73(9):2408-16. PMID: 7513251.
      Citations:    Fields:    Translation:Humans
    236. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 1994 Apr; 31(2 Suppl 3):36-43. PMID: 8073308.
      Citations: 2     Fields:    Translation:Humans
    237. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994 Mar; 12(3):575-9. PMID: 8120556.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    238. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs. 1994; 12(3):217-22. PMID: 7896540.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    239. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 1994; 5 Suppl 2:59-63. PMID: 8204521.
      Citations: 4     Fields:    Translation:Humans
    240. Preti A, Hagemeister FB, McLaughlin P, Swan F, Rodriguez A, Besa P, Cox JD, Allen PK, Cabanillas F. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol. 1994; 5 Suppl 2:97-100. PMID: 7515653.
      Citations: 2     Fields:    Translation:Humans
    241. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol. 1994; 5 Suppl 2:73-7. PMID: 7515650.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    242. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol. 1994; 5 Suppl 2:41-6. PMID: 8204519.
      Citations: 2     Fields:    Translation:Humans
    243. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993 Jun; 11(6):1108-11. PMID: 8501496.
      Citations: 11     Fields:    Translation:Humans
    244. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8. PMID: 8374522.
      Citations: 3     Fields:    Translation:Humans
    245. Liang JC, Bailey NM, Gabriel GJ, Kattan MW, Wang RY, Hagemeister FB, Cabanillas FF, Fuller LM. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. Leuk Lymphoma. 1993 Apr; 9(6):503-8. PMID: 7687918.
      Citations:    Fields:    Translation:Humans
    246. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol. 1993 Mar; 4(3):205-11. PMID: 7682436.
      Citations: 6     Fields:    Translation:Humans
    247. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol. 1993 Feb; 4(2):125-31. PMID: 8448080.
      Citations: 13     Fields:    Translation:Humans
    248. Hagemeister FB. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology. Leuk Lymphoma. 1993; 10 Suppl:21-7. PMID: 7683228.
      Citations:    Fields:    Translation:Humans
    249. Hagemeister FB. Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leuk Lymphoma. 1993; 10 Suppl:91-7. PMID: 7683230.
      Citations:    Fields:    Translation:Humans
    250. Spinolo JA, Jagannath S, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA, Vel?squez W. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leuk Lymphoma. 1993 Jan; 9(1-2):71-7. PMID: 8477204.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    251. Cabanillas F, McLaughlin P, Swan F, Hagemeister F, Romaguera J, Rodr?guez J, Rodr?guez M. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol. 1992 Nov; 3(9):711-7. PMID: 1450060.
      Citations: 11     Fields:    Translation:Humans
    252. Hagemeister FB, Fuller L, McLaughlin P, Rodriguez M, Romaguera J, Swan F, Cabanillas F. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol. 1992 Sep; 3 Suppl 4:87-90. PMID: 1450086.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    253. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May; 10(5):790-4. PMID: 1373760.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    254. Spinolo JA, Cabanillas F, Dixon DO, Khorana SM, McLaughlin P, Velasquez WS, Hagemeister FB, Redman JR, Swan F. Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Ann Oncol. 1992 Mar; 3(3):227-32. PMID: 1586621.
      Citations: 4     Fields:    Translation:Humans
    255. Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood. 1992 Feb 15; 79(4):1024-8. PMID: 1737086.
      Citations: 6     Fields:    Translation:Humans
    256. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1992; 23(2):407-12. PMID: 1587764.
      Citations: 17     Fields:    Translation:Humans
    257. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis. 1991 Jul; 10(7):551-8. PMID: 1915397.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    258. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991 May 15; 114(10):855-60. PMID: 2014946.
      Citations: 13     Fields:    Translation:Humans
    259. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB, Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol. 1991 May; 9(5):762-9. PMID: 1707956.
      Citations: 12     Fields:    Translation:Humans
    260. Velasquez WS, Fuller LM, Jagannath S, Tucker SL, North LB, Hagemeister FB, McLaughlin P, Swan F, Redman JR, Rodriguez MA, et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood. 1991 Mar 01; 77(5):942-7. PMID: 1704805.
      Citations: 3     Fields:    Translation:Humans
    261. Robertson LE, Redman JR, Butler JJ, Osborne BM, Velasquez WS, McLaughlin P, Swan F, Rodriguez MA, Hagemeister FB, Fuller LM, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991 Feb; 9(2):236-42. PMID: 1988571.
      Citations: 10     Fields:    Translation:Humans
    262. McLaughlin P, Fuller L, Redman J, Hagemeister F, Durr E, Allen P, Holmes L, Velasquez W, Swan F, Cabanillas F. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol. 1991 Feb; 2 Suppl 2:137-40. PMID: 1710918.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    263. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol. 1991 Jan; 2(1):25-31. PMID: 2009233.
      Citations: 1     Fields:    Translation:Humans
    264. Hagemeister FB, Cabanillas F, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Swan F, Vel?squez WS, Rodr?guez MA, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40. PMID: 2259922.
      Citations:    Fields:    Translation:HumansCells
    265. Romagurea JE, Velasquez WS, Silvermintz KB, Fuller LB, Hagemeister FB, McLaughlin P, Cabanillas F. Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. Cancer. 1990 Jul 15; 66(2):267-72. PMID: 2369711.
      Citations: 10     Fields:    Translation:Humans
    266. Givens SS, Fuller LM, Hagemeister FB, Gehan EA. Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone. Cancer. 1990 Jul 01; 66(1):69-74. PMID: 2354411.
      Citations:    Fields:    Translation:Humans
    267. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990 Apr; 8(4):615-22. PMID: 2313330.
      Citations: 6     Fields:    Translation:Humans
    268. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin's disease. Cancer. 1990 Mar 01; 65(5):1090-6. PMID: 2302660.
      Citations: 6     Fields:    Translation:Humans
    269. Sen P, Bailey NM, Hagemeister FB, Liang JC. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res. 1990 Feb 01; 50(3):558-62. PMID: 1688733.
      Citations: 1     Fields:    Translation:HumansCells
    270. Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol. 1989 Dec; 7(12):1791-9. PMID: 2479719.
      Citations: 23     Fields:    Translation:HumansCells
    271. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct; 7(10):1518-27. PMID: 2674337.
      Citations: 29     Fields:    Translation:Humans
    272. Fesus SM, Hagemeister FB, Manning J. Hodgkin disease in a patient with common variable immunodeficiency. Am J Hematol. 1989 Oct; 32(2):138-42. PMID: 2757010.
      Citations: 1     Fields:    Translation:Humans
    273. Cabanillas F, Pathak S, Grant G, Hagemeister FB, McLaughlin P, Swan F, Rodriguez MA, Trujillo J, Cork A, Butler JJ, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med. 1989 Aug; 87(2):167-72. PMID: 2757057.
      Citations: 8     Fields:    Translation:HumansCells
    274. Fuller LM, Hagemeister FB, Velasquez WS, Sullivan MP. Hodgkin's disease and non-Hodgkin's lymphomas. Compr Ther. 1989 Aug; 15(8):3-11. PMID: 2670408.
      Citations:    Fields:    Translation:Humans
    275. Velasquez WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR, Swan F, Hagemeister FB, McLaughlin P, Cabanillas F. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood. 1989 Aug 01; 74(2):551-7. PMID: 2752132.
      Citations: 24     Fields:    Translation:Humans
    276. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb; 7(2):179-85. PMID: 2644397.
      Citations: 15     Fields:    Translation:Humans
    277. Fuller LM, Hagemeister FB. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease. Recent Results Cancer Res. 1989; 117:197-204. PMID: 2602645.
      Citations:    Fields:    Translation:Humans
    278. Spinolo JA, Jagannath S, Dicke KA, Smith KE, Cabanillas F, Hagemeister FB, Horwitz LJ, McLaughlin P, Swan F, Spitzer G. High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience. Recent Results Cancer Res. 1989; 117:233-8. PMID: 2602646.
      Citations:    Fields:    Translation:Humans
    279. McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988 Nov 02; 80(17):1408-12. PMID: 3172268.
      Citations: 6     Fields:    Translation:Humans
    280. Cabanillas F, Pathak S, Trujillo J, Manning J, Katz R, McLaughlin P, Velasquez WS, Hagemeister FB, Goodacre A, Cork A, et al. Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma. Cancer Res. 1988 Oct 01; 48(19):5557-64. PMID: 3416308.
      Citations: 5     Fields:    Translation:Humans
    281. van der Velden JW, van Putten WL, Guinee VF, Pfeiffer R, van Leeuwen FE, van der Linden EA, Vardomskaya I, Lane W, Durand M, Lagarde C, et al. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer. 1988 Aug 15; 42(2):252-5. PMID: 3403068.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    282. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol. 1988 Aug; 6(8):1293-302. PMID: 3411342.
      Citations: 2     Fields:    Translation:Humans
    283. Hagemeister FB. Prognostic factors in decision-making in the clinical management of Hodgkin's disease. Hematol Oncol. 1988 Jul-Sep; 6(3):257-69. PMID: 3042583.
      Citations: 1     Fields:    Translation:Humans
    284. Cabanillas F, Pathak S, Trujillo J, Grant G, Cork A, Hagemeister FB, Velasquez WS, McLaughlin P, Redman J, Katz R, et al. Cytogenetic features of Hodgkin's disease suggest possible origin from a lymphocyte. Blood. 1988 Jun; 71(6):1615-7. PMID: 3370310.
      Citations: 6     Fields:    Translation:HumansCells
    285. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):47-50. PMID: 3041599.
      Citations: 5     Fields:    Translation:Humans
    286. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys. 1988 Apr; 14(4):683-92. PMID: 3280532.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    287. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan; 71(1):117-22. PMID: 3334893.
      Citations: 78     Fields:    Translation:Humans
    288. Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987 Oct; 5(10):1670-2. PMID: 3655864.
      Citations: 4     Fields:    Translation:Humans
    289. North LB, Fuller LM, Sullivan-Halley JA, Hagemeister FB. Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology. 1987 Sep; 164(3):599-602. PMID: 3112862.
      Citations: 5     Fields:    Translation:Humans
    290. Lee MS, Blick MB, Pathak S, Trujillo JM, Butler JJ, Katz RL, McLaughlin P, Hagemeister FB, Velasquez WS, Goodacre A, et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood. 1987 Jul; 70(1):90-5. PMID: 3297209.
      Citations: 8     Fields:    Translation:HumansCells
    291. McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA, Dixon DO. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol. 1987 Jun; 5(6):867-74. PMID: 3295130.
      Citations: 5     Fields:    Translation:Humans
    292. McLaughlin P, Cabanillas F, Hagemeister FB, Velasquez WS. Activity of bisantrene in refractory lymphoma. Cancer Treat Rep. 1987 Jun; 71(6):631-3. PMID: 3581102.
      Citations:    Fields:    Translation:Humans
    293. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987 Apr; 5(4):556-61. PMID: 3559649.
      Citations: 14     Fields:    Translation:Humans
    294. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987 Mar; 5(3):407-12. PMID: 3819806.
      Citations: 20     Fields:    Translation:Humans
    295. Newell GR, Cabanillas FG, Hagemeister FJ, Butler JJ. Incidence of lymphoma in the US classified by the working formulation. Cancer. 1987 Feb 15; 59(4):857-61. PMID: 3802044.
      Citations: 4     Fields:    Translation:Humans
    296. Kalter SP, Riggs SA, Cabanillas F, Butler JJ, Hagemeister FB, Mansell PW, Newell GR, Velasquez WS, Salvador P, Barlogie B, et al. Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood. 1985 Sep; 66(3):655-9. PMID: 4027383.
      Citations: 6     Fields:    Translation:Humans
    297. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer. 1985 Feb 15; 55(4):691-7. PMID: 2578302.
      Citations: 6     Fields:    Translation:Humans
    298. Dixon C, Hagemeister F, Legha S, Bodey G. Pulmonary toxicity associated with spirogermanium. Cancer Treat Rep. 1984 Jun; 68(6):907-8. PMID: 6733705.
      Citations: 3     Fields:    Translation:Humans
    299. da Cunha MF, Meistrich ML, Fuller LM, Cundiff JH, Hagemeister FB, Velasquez WS, McLaughlin P, Riggs SA, Cabanillas FF, Salvador PG. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol. 1984 Jun; 2(6):571-7. PMID: 6547167.
      Citations: 30     Fields:    Translation:Humans
    300. Velasquez W, Fuller LM, Oh KK, Hagemeister FB, Sullivan JA, Manning JT, Shullenberger CC. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas. Cancer. 1984 Apr 01; 53(7):1478-83. PMID: 6199100.
      Citations: 1     Fields:    Translation:Humans
    301. Perez-Soler R, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT, Fuller LM, Cabanillas F. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol. 1984 Apr; 2(4):260-6. PMID: 6368759.
      Citations: 7     Fields:    Translation:Humans
    302. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol. 1983 Aug; 19(8):1091-6. PMID: 6352279.
      Citations: 2     Fields:    Translation:Humans
    303. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul; 1(7):432-9. PMID: 6199478.
      Citations: 2     Fields:    Translation:Humans
    304. Fuller LM, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer. 1983 Jun 15; 51(12 Suppl):2469-76. PMID: 6687831.
      Citations: 2     Fields:    Translation:Humans
    305. Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger CC. Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer. 1982 Dec 01; 50(11):2307-13. PMID: 6754064.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    306. Thomas JL, Bernardino ME, Vermess M, Barnes PA, Fuller LM, Hagemeister FB, Doppman J, Fisher RI, Longo DL. EOE-13 in the detection of hepatosplenic lymphoma. Radiology. 1982 Dec; 145(3):629-34. PMID: 6292995.
      Citations:    Fields:    Translation:Humans
    307. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982 Sep; 60(3):693-7. PMID: 7104493.
      Citations: 26     Fields:    Translation:Humans
    308. Hagemeister FB, Fuller LM, Velasquez WS, Sullivan JA, North L, Butler JJ, Johnston DA, Shullenberger CC. Stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep. 1982 Apr; 66(4):789-98. PMID: 7074649.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    309. Thomas JL, Barnes PA, Bernardino ME, Hagemeister FB. Limited CT studies in monitoring treatment of lymphoma. AJR Am J Roentgenol. 1982 Mar; 138(3):537-9. PMID: 7039271.
      Citations: 1     Fields:    Translation:Humans
    310. North LB, Fuller LM, Hagemeister FB, Rodgers RW, Butler JJ, Shullenberger CC. Importance of initial mediastinal adenopathy in Hodgkin disease. AJR Am J Roentgenol. 1982 Feb; 138(2):229-35. PMID: 6976723.
      Citations: 4     Fields:    Translation:Humans
    311. Hagemeister FB, Fuller LM, Sullivan JA, North L, Velasquez W, Conrad FG, McLaughlin P, Butler JJ, Shullenberger CC. Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology. 1981 Dec; 141(3):783-9. PMID: 6895415.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    312. Osborne BM, Hagemeister FB, Butler JJ. Extranodal gastrointestinal sinus histiocytosis with massive lymphadenopathy. Clinically presenting as a malignant tumor. Am J Surg Pathol. 1981 Sep; 5(6):603-11. PMID: 7325277.
      Citations: 2     Fields:    Translation:Humans
    313. Rodgers RW, Fuller LM, Hagemeister FB, Johnston DA, Sullivan JA, North LB, Butler JJ, Velasquez WS, Conrad FG, Shullenberger CC. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer. 1981 May 01; 47(9):2196-203. PMID: 7226112.
      Citations: 4     Fields:    Translation:Humans
    314. Fuller LM, Madoc-Jones H, Hagemeister FB, Rodgers RW, North LB, Butler JJ, Martin RG, Gamble JF, Shullenberger CC. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys. 1980 Jul; 6(7):799-808. PMID: 7204116.
      Citations: 2     Fields:    Translation:Humans
    315. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7. PMID: 7388758.
      Citations: 38     Fields:    Translation:Humans
    316. Liposomal tretinoin. Blood. 96.
    317. Allogeneic hematopoietic transplantation for indolent lymphomas. Blood. 96.
    318. Diffuse undifferentiated lymphoma (DUL). 780.
    319. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plastic and Reconstructive Surgery.
    320. Erratum. Cancer. 97:3131.
    321. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. The Lancet Oncology. 15:69-77.
    322. Mitoxantrone as monotherapy versus combination therapy. Seminars in Oncology. 17:41-43.
    323. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    324. Merkel cell carcinoma. Cancer Bulletin. 47:175-177.
    325. New approaches to management of stage IV Hodgkin's disease. Cancer Bulletin. 35:230-232.
    326. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. British Journal of Haematology.
    327. New approaches to management of Hodgkin's disease designed to minimize long-term sequelae. Cancer Bulletin. 41:88-93.
    328. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    329. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    330. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    331. Prognostic factors for stage IV Hodgkin's disease (HD) treated with MOPP.
    332. Treatment options for stage III Hodgkin's disease. Cancer Bulletin. 35:224-229.
    333. Controversies in the management of early stage Hodgkin's disease. Cancer Research Therapy and Control. 7:259-265.
    334. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology.
    335. Hodgkin's lymphoma in the elderly. Oncology. 21.
    336. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma. British Journal of Haematology.
    337. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    338. Treatment of non-Hodgkin's lymphoma (NHL) with cytosine arabinoside arabinoside (ARA-C) and 6-thioguanine (6-TG). 967.
    339. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 100:e454-e457.
    340. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    341. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    342. The FLIPI and the R-FLIPI. American Journal of Hematology/ Oncology. 6:364-368.
    343. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    344. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    345. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.
    346. Hodgkin's disease stage I and II. Management considerations and results in adults. Cancer Bulletin. 35:218-223.
    347. Factors predicting for complete remission (CR) in patients (PTS) with recurrent lymphoma treated with salvage combination chemotherapy.
    348. Burkitt's lymphoma. Cancer Bulletin. 33:295-297.
    349. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology.
    350. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation.
    HAGEMEISTER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (631)
    Explore
    _
    Co-Authors (139)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _